An Introduction to Viral Infections
Viruses are intracellular parasites, and are the most widespread organisms on Earth. They cause acute disease, such as gastroenteritis or influenza, or chronic disease, such as HIV or hepatitis. Emerging infections, such as SARS, MERS, avian influenza, Ebola and most recently, the devastating SARS-Cov-2 pandemic pose an increasing threat to human health. Numerous substances with antiviral activity are in clinical use. The use of protease inhibitors and highly active antiretroviral therapy has transformed the management of HIV. Promising emerging therapeutic approaches include neutralising antibodies. In addition, the current success of mRNA vaccines against SARS-Cov-2 heralds a new era of vaccinology. However, the threat of drug- and vaccine-resistant viral mutants are a major problem.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Our supporting partners do not constitute an endorsement of the content on this page.
Viral Infections Content
18th European AIDS Conference 2021: Welcome from Sanjay Bhagani
Dr Sanjay Bhagani invites you to join the 18th European AIDS Conference (EACS 2021). The conference will be organised in a hybrid format from October 27-30, 2021. The onsite Conference in London will take place, following a comprehensive COVID-19 health and safety concept, complemented by an engaging and interactive online platform that mirrors the scientific […]
Christoph Spinner, IAS 2021: Results from the DISCOVER Open Label Study
We had the pleasure to meet with Christoph Spinner (University Hospital rechts der Isar, Technical University of Munich (TUM), Munich, Germany) to discuss the DISCOVER open label phase results. The abstract entitled: ‘Outcomes of participants switching from F/TDF to F/TAF for PrEP: week 48 results from the DISCOVER open label phase’ was presented at IAS […]
Tomas Jelinek: Unmet Needs, Prevention and Treatment of Chikungunya
It was a great pleasure to meet with Tomas Jelinek (The Berlin Center for Travel and Tropical Medicine, Berlin, Germany) to discuss chikungunya virus, its health burden and the unmet needs in its prevention and treatment. Question: Could you tell us a little about chikungunya, its health burden and the unmet needs in its prevention […]
Lulu Nair, IAS 2021: The Health Burden of HIV among Young Women in Africa
touchINFECTIOUSDISEASES were pleased to meet with Lulu (Gonasagrie) Nair (Stellenbosch University, Stellenbosch, South Africa) to discuss the the health burden of HIV among young women and adolescent girls in Africa, and the need for pre-exposure prophylaxis. The abstract entitled: ‘Adherence to the dapivirine vaginal ring and oral PrEP among adolescent girls and young women in […]
Lulu Nair, IAS 2021: Interim Results from the REACH study
touchINFECTIOUSDISEASES were pleased to meet with Lulu (Gonasagrie) Nair (Stellenbosch University, Stellenbosch, South Africa) to discuss the interim results from the REACH study. The abstract entitled: ‘Adherence to the dapivirine vaginal ring and oral PrEP among adolescent girls and young women in Africa: interim results from the REACH study’ was presented at IAS 2021 – […]
Heiner Wedemeyer, EASL ILC 2021: Bulevirtide Phase 3 Hepatitis D Study
It was a pleasure to be able to speak to Prof. Heiner Wedemeyer (Hannover Medical School, Hannover, Germany) about the interim results from the phase 3 MYR301 study investigating bulevirtide monotherapy in patients with chronic hepatitis D. His abstract entitled ‘Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24 weeks […]
Tobias Boettler, EASL ILC 2021: Hepatitis Highlights
As always, it was a pleasure to meet our Expert Faculty Member, Dr Tobias Boettler (University of Freiburg, Freiburg, Germany) following the EASL ILC 2021 conference. This time we discuss his highlights from the recent meeting in the field of hepatitis. Questions Could you give us an overview of what we learned about the antiviral […]
Timothy Hinks, ECCMID 2021: ATOMIC2 Study Results
touchINFECTIOUSDISEASES were pleased to meet with Timothy Hinks (Nuffield Department of Medicine, University of Oxford, Oxford, UK) to discuss the results of the ATOMIC2 study results, investigating azithromycin in the treatment of COVID-19. The abstract entitled: ‘A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19: the ATOMIC2 trial’ was presented at the […]
Beatriz Mateos, EASL ILC 2021: Tenofovir in Hepatitis B Patients with COVID-19
It was lovely to speak with Dr Beatriz Mateos (Universidad de Alcalá, Madrid, Spain) about the findings from her research into the impact of tenofovir on the severity of COVID-19 infection in those with chronic hepatitis B. Her presentation entitled ‘Tenofovir reduces the severity of COVID-19 infection in chronic hepatitis B patients’ was given at […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!